OmnisOva is an avian genetics company working with the global poultry industry.
We work across the whole spectrum — the bird and the egg — and we are interested in the egg’s full potential: as a food, as a medicine, and as a manufacturing system.
THE SCIENCE
Our starting point is the egg itself, and what it contains.
Understanding which proteins an egg carries, and what becomes possible when one of them is absent, is the foundation everything else builds on.
APA 7th: Mine, Y., Guyonnet, V., Hatta, H., Nau, F., & Qiu, N. (Eds.). (2023). Handbook of egg science and technology (1st ed.). CRC Press. https://doi.org/10.1201/9781003254430
OUR WORKFood.
A food the world already shares, opened up.
Egg allergy is one of the most common food allergies in early childhood worldwide. The ambition is inclusion: a food the world already shares, opened up to the people it has always left out.
The dominant allergen in egg is ovomucoid and our work is directed at developing a Ovomucoid (OVM) free egg that is low allergen.
Medicine.
The same facilities, the same method — a modified input.
Influenza and several other viral vaccines are predominantly manufactured in fertile eggs, and will continue to rely on eggs until alternative technologies become standard e.g. mRNA, cell-based or subunit.
An egg without the dominant allergen is an input to that system with improved production and quality of vaccines natural adjacency to our core work, and ones we are exploring.
Manufacture.
The humble chicken egg is already a manufacturing platform.
The egg is already a manufacturing platform. Vaccine production has relied on it for decades, and the industrial infrastructure exists at scale.
Longer term, the interesting question is what else that platform could make.
Better Birds.
Better eggs for a better world.
We are also investigating the use of genetic technologies for a range of outcomes, including improved disease resilience of poultry layer flocks.
Better science, better birds, better eggs.
These are directions, not limits. If you have an idea involving a bird or an egg, come and talk to us.
We challenge traditional thinking and pioneer the science to create better eggs for a better world, looking across the full avian ecosystem, changing what is possible.
Omnis – everyone’s. Ova – egg.
Talk to us
Manufacturers, retailers, researchers, investors — or anyone with an idea involving a bird or an egg.
yolanda.uys@omnisova.com
Contact us
THE PEOPLE BEHIND ITBoard
Warren Bingham
EXECUTIVE CHAIRMAN
Warren Bingham is a Board Chair and strategic leader driving high-impact innovation across medtech, biotech, food, and agriculture. With 30+ years' experience spanning commercialisation, governance, and global scale, he is Founder and Executive Chairman of MedTech International, advising CEOs, boards, and investors, while chairing Agscent, OmnisOva, Ferronova and BIOMOTUM, and serving as Vice Chair of the MTAA. He previously launched Given Imaging's ANZ subsidiary, bringing PillCam® to Australia and securing the world's first national reimbursement ahead of the company's $1B acquisition. Warren mentors emerging founders through CSIRO ON, Remarkable, and Taronga HATCH, and champions social impact as a Diabetes Australia Ambassador and Vinnies CEO Sleepout Ambassador.
Prof. Kirsten Perrett PhD
INDEPENDENT DIRECTOR
Professor Kirsten Perrett is a paediatric allergist, vaccinologist and clinician-scientist at the Murdoch Children's Research Institute, the Royal Children's Hospital and the University of Melbourne. She is Director of the National Allergy Centre of Excellence and the NHMRC Centre of Research Excellence in Food Allergy and leads the Population Allergy Research Group at MCRI. Over 20 years, she has led more than 30 vaccine and food allergy clinical trials, attracted over $65 million in research funding, and published over 160 peer-reviewed papers. Her work has shaped global approaches to food allergy prevention, diagnosis and management.
Steven Murphy
NON-EXECUTIVE DIRECTOR
Steve is an experienced director with an enduring record of leadership and governance. He brings decisive strategic judgement shaped by more than 25 years at the helm of Perfection Private, a developer/investor in commercial and industrial real estate, with a growing portfolio of businesses in technology and science. Working with a small, high‑performing team, Steve focuses on clarity, accountability and long‑range vision to deliver consistently strong commercial performance. Outside of work, he’s an avid billiards player and ancient history buff.
Rob McInnes
NON-EXECUTIVE DIRECTOR
Rob McInnes is an intellectual property lawyer, investor and company director with more than 30 years’ experience in the commercialisation of science and technology. He specialises in structuring and negotiating licensing, research and development and other technology transactions, and in intellectual property strategy and due diligence. Originally trained as a chemist, Rob has also managed intellectual property and technology transfer in-house for a multinational company. He is an angel investor, a limited partner in several venture capital funds, and a mentor and adviser to technology start-ups - bringing legal, commercial and investment perspectives to the development and commercialisation of innovative technologies.
Lindsay Holloway
NON-EXECUTIVE DIRECTOR
Lindsay Holloway is Executive Chair of William Buck Victoria and former Managing Partner of William Buck Melbourne, where he led the firm for 19 years, overseeing significant growth and upholding strong technical, ethical and people-centred standards. A Fellow Chartered Accountant with more than 35 years’ experience, Lindsay has deep expertise in risk management, strategic planning, professional services, manufacturing, NFPs and board advisory. He has held leadership roles across the William Buck network, including Deputy Chair and Head of Risk. Lindsay is also a Board Advisor to medtech start-up Incite Health.
Lionel Henderson
EXECUTIVE DIRECTOR
Lionel Henderson is an experienced Company Director, having been a director or company secretary since 2004. He was a Director of Business Development & Commercial with CSIRO for 17 years, where he participated in the spin out of 7 start-up companies, developed several research alliances and collaboration frameworks, including public – private partnerships, and managed CSIRO’s involvement in multiple CRCs. Lionel has overseen the licensing for a range of CSIRO’s technologies domestically and internationally and has been a member and Chair of a number of external committees for CSIRO.
Lionel is also a Director of Arista Cereal Technologies, another CSIRO spin out company, commercialising products in the food industry, HeartKids Ltd, a children focussed charity and is a consultant for a number of commercialisation projects for Australian universities.
Management
Greg Davis
CHIEF EXECUTIVE OFFICER
Greg Davis brings more than 30 years of senior leadership experience across retail and consumer businesses. His previous roles include Chief Operating Officer and Chief Commercial Officer of Coles, CEO of Coles Express and senior leadership roles with ALDI Australia. Greg has led large and complex businesses and brings extensive experience in commercial strategy, business transformation and building organisations for growth Greg holds a Bachelor of Commerce in Economics from the University of Newcastle and completed the Stanford Executive Program at Stanford Graduate School of Business.
Tim Doran PhD
CHIEF SCIENTIFIC OFFICER
Tim in an internationally recognised scientist and has worked for 30 years developing and applying post-genomic technologies to global livestock industries. Tim’s primary focus is avian genetics, where he has worked closely with industry to improve health, welfare, productivity, sustainability and food safety in poultry production systems. Tim has published more than 80 peer reviewed papers including one in the scientific journal Nature describing work he undertook in collaboration with Dr Craig Smith at Monash University to help solve the long-standing mystery of sex determination in birds. Tim is also an inventor on 13 patents and is passionate about translating research to real world impacts.
Yolanda Uys
CHIEF OPERATING OFFICER
Yolanda Uys is a C-suite commercial executive with 25 years of experience across FMCG, retail and hospitality having lived and managed brands in Europe, Africa, Australia and the UK. Her career spans private equity-backed and publicly listed environments, including Chief Marketing Officer Crown Resorts — a Blackstone-owned business — , Chief Marketing Officer Reece, General Manager Coles, Dan Murphy's, Stella Artois UK - part of AB InBev and Global Innovation Manager Cadbury. She co-founded Banks Botanicals, an Australian lifestyle beverage company built from concept to acquisition by Alchemy Distilling in 2025, with exports to Singapore and the Middle East. Yolanda holds a GAICD and serves as a Non-Executive Director at the Institute for Educational Reform. She lectures at RMIT as part of the Innovation accelerator and activator programs and is based in Melbourne.
Tony Hood
GENERAL MANAGER FINANCE
Tony Hood brings 27 years of corporate finance experience spanning capital raising and corporate governance across multiple industries. He holds an MBA and a degree in Economics, underpinning a disciplined, numbers-driven approach to business strategy. Tony's career spans technology, avian tourism, flour milling, and animal husbandry, giving him broad cross-sector commercial insight. Over the past decade he has specialised in commercialising science, translating early-stage research into investable, market-ready ventures. For the last five years his focus has centred specifically on avian species, combining deep industry knowledge with financial rigour to drive Omnisova's growth and commercialisation strategy. Tony is a Responsible Manager under an Australian Financial Services Licence and is a licenced auctioneer.